Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE)
Heart Rhythm · 2025-08 · 22 (8) · 1975-1983
DOI: 10.1016/j.hrthm.2025.04.033 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Heart Rhythm, 2025-08. Verfasst von Koonlawee Nademanee und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,…. Hauptthemen laut MEDLINE: Ventricular Fibrillation, Brugada Syndrome, Catheter Ablation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biosense Webster Inc, National Research Council of Thailand.
Abstract (Originalsprache)
BACKGROUND: Catheter ablation has emerged as a promising treatment to prevent ventricular fibrillation (VF) in Brugada syndrome (BrS). However, evidence from a prospective, randomized clinical trial is lacking. OBJECTIVE: The Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes trial is a prospective, multicenter, 2-arm, randomized (1:1), open-label clinical study designed to evaluate the efficacy and safety of ablation therapy in patients with symptomatic BrS. METHODS: We enrolled patients with symptomatic BrS with an implantable cardioverter-defibrillator. Patients were randomized to ablation therapy or control groups. Ablation targeted arrhythmogenic areas identified through electroanatomical mapping, predominantly at the right ventricular epicardium. The primary outcome was the first occurrence of VF or death. One interim analysis was planned after 50 patients were randomized. RESULTS: Of 67 patients screened, 52 were randomized (25 to ablation, 25 to control, 2 withdrawals), and 15 declined randomizations but remained in a registry (10 chose ablation, 5 opted against ablation). After 3 years of follow-up, the ablation group had significantly fewer VF events than the control group (hazard ratio, 0.288; P = .0184). At the interim analysis, the Data Safety Monitoring Board recommended early trial termination. Among all ablation recipients (including crossovers and registry participants), 83% remained VF free after a single procedure and 90% after a repeat ablation. Complications of ablation included 1 hemopericardium without a long-term sequel. CONCLUSION: Epicardial substrate ablation significantly reduces VF recurrence in patients with symptomatic BrS with implantable cardioverter-defibrillators and seems safe, supporting its potential role as a first-line therapy to prevent recurrent VF in patients with symptomatic BrS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Heart Institute, Bumrungrad Hospital, Bangkok, Thailand; Pa…
- Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Maharat Nakhon Ratchasima Hospital, Nakorn Ratchasima, Thailand.
- Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Förderung
- Biosense Webster Inc
- National Research Council of Thailand
Zitieren
APA
Nademanee, K., Wongcharoen, W., Chimparlee, N., Chokesuwattanaskul, R., Annueypol, M., Phusunti, K., Sahasatas, D., Prechawat, S., Prasertwitayakij, N., Makarawate, P., Sutjaporn, B., Wilde, A., Drew, C., Postema, P. G., Ngarmukos, T., Vardhanabhuti, S., Veerakul, G., Wandee, P., Mauleekoonphairoj, J., …, & Khongphatthanyaothin, A. (2025). Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE). Heart Rhythm, 22(8), 1975-1983. https://doi.org/10.1016/j.hrthm.2025.04.033
Vancouver
Nademanee K, Wongcharoen W, Chimparlee N, Chokesuwattanaskul R, Annueypol M, Phusunti K, et al. Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE). Heart Rhythm. 2025;22(8):1975-1983. doi:10.1016/j.hrthm.2025.04.033
BibTeX
@article{Nademanee2025,
author = {Nademanee, Koonlawee and Wongcharoen, Wanwarang and Chimparlee, Nitinan and Chokesuwattanaskul, Ronpichai and Annueypol, Montawatt and Phusunti, Keerapa and Sahasatas, Dujdao and Prechawat, Somchai and Prasertwitayakij, Narawudt and Makarawate, Pattarapong and Sutjaporn, Boosamas and Wilde, Arthur and Drew, Carla and Postema, Pieter G and Ngarmukos, Tachapong and Vardhanabhuti, Saran and Veerakul, Gumpanart and Wandee, Pharawee and Mauleekoonphairoj, John and Poovorawan, Yong and Khongphatthanyaothin, Apichai},
title = {Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE)},
journal = {Heart Rhythm},
year = {2025},
volume = {22},
number = {8},
pages = {1975--1983},
doi = {10.1016/j.hrthm.2025.04.033}
}
EUVIMED